Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

Five-year commercialisation activity at the university is on the rise in terms of patents, inventions and licensing revenue.

University endowment-backed Will Ventures aims to unlock sports-related innovation across markets such as fitness, media and gaming.

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Returning investor SoftBank Vision Fund came back for a round that valued the consumer product delivery platform at $3.9bn.

The Comcast, American Express and Amazon-backed grocery delivery service increased its valuation to $17.7bn in a round co-led by Valiant Peregrine Fund and D1 Capital Partners.

Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

Vector Capital is acquiring the data integration platform developer three years after NTT invested and five after it secured a $1bn valuation.

Existing investors CBRE, Engie New Ventures and Evergy Ventures returned for a round that will help the energy efficiency retrofitter expand its product offering.

Applied Ventures contributed to a $50m round that pushed the total raised by the silicon photonics technology producer to $225m.